The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts
Open accessAbstract
INTRODUCTION: Medical advances have led to an increase in the world's population of immunosuppressed individuals. The most severely immunocompromised patients are those who have been diagnosed with a hematologic malignancy, solid organ tumor, or who have other conditions that require immunosuppressive therapies and/or solid organ or stem cell transplants. MATERIALS AND METHODS: Medically attended patients with a positive clinical diagnosis of influenza were recruited prospectively and clinically evaluated. Nasal washes and serum were collected. Evaluation of viral shedding, nasal and serum cytokines, clinical illness, and clinical outcomes were performed to compare severely immunocompromised individuals to nonimmunocompromised individuals with influenza infection. RESULTS: Immunocompromised patients with influenza had more severe disease/complications, longer viral shedding, and more antiviral resistance while demonstrating less clinical symptoms and signs on clinical assessment. CONCLUSIONS: Immunocompromised patients are at risk for more severe or complicated influenza induced disease, which may be difficult to prevent with existing vaccines and antiviral treatments. Specific issues to consider when managing a severely immunocompromised host include the development of asymptomatic shedding, multi-drug resistance during prolonged antiviral therapy, and the potential high risk of pulmonary involvement. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00533182.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unicef, U. (2011) · Cited by 1,292
Hematopoietic Stem Cell Transplantation<subtitle>A Global Perspective</subtitle>
Gratwohl, A. (2010) · JAMA · doi:10.1001/jama.2010.491 · Cited by 672
Mediator Release after Nasal Airway Challenge with Allergen
Naclerio, R. M., Creticos, P. S., Norman, P. S., & Lichtenstein, L. M. (1986) · American Review of Respiratory Disease · doi:10.1164/arrd.1986.134.5.1102 · Cited by 562
Nichols, W. G., Guthrie, K. A., Corey, L., & Boeckh, M. (2004) · Clinical Infectious Diseases · doi:10.1086/425004 · Cited by 377
Kumar, D., Michaels, M. G., Morris, M. I., Green, M., Avery, R. K., Liu, C., Danziger-Isakov, L., Stosor, V., Estabrook, M., Gantt, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70133-x · Cited by 359
Self-citationRecovery of Drug‐Resistant Influenza Virus from Immunocompromised Patients: A Case Series
Ison, M. G., Gubareva, L. V., Atmar, R. L., Treanor, J., & Hayden, F. G. (2006) · The Journal of Infectious Diseases · doi:10.1086/500465 · Cited by 261
Lin, J. C., & Nichol, K. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.441 · Cited by 197
Kim, Y.-J., Boeckh, M., & Englund, J. (2007) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2007-976494 · Cited by 195
Baz, M., Abed, Y., McDonald, J., & Boivin, G. (2006) · Clinical Infectious Diseases · doi:10.1086/508777 · Cited by 179
Incidence and Temporal Trends of Primary Immunodeficiency: A Population-Based Cohort Study
Joshi, A. Y., Iyer, V. N., Hagan, J. B., St. Sauver, J. L., & Boyce, T. G. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.1.16 · Cited by 164
Cited by
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716197 · Cited by 925
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Paules, C., & Subbarao, K. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30129-0 · Cited by 740
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
D’Antiga, L. (2020) · Liver Transplantation · doi:10.1002/lt.25756 · Cited by 664
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573
Uyeki, T. M., Hui, D. S., Zambon, M., Wentworth, D. E., & Monto, A. S. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00982-5 · Cited by 560
Community Mitigation Guidelines to Prevent Pandemic Influenza — United States, 2017
Qualls, N., Levitt, A., Kanade, N., Wright-Jegede, N., Dopson, S., Biggerstaff, M., Reed, C., Uzicanin, A., CDC Community Mitigation Guidelines Work Group, Levitt, A., et al. (2017) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6601a1 · Cited by 471
Monti, S., Balduzzi, S., Delvino, P., Bellis, E., Quadrelli, V. S., & Montecucco, C. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217424 · Cited by 446
Prevalence of Immunosuppression Among US Adults, 2013
Harpaz, R., Dahl, R. M., & Dooling, K. L. (2016) · JAMA · doi:10.1001/jama.2016.16477 · Cited by 266
Human Influenza Virus Infections
Peteranderl, C., Schmoldt, C., & Herold, S. (2016) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0036-1584801 · Cited by 259
Dhanasekaran, V., Sullivan, S., Edwards, K. M., Xie, R., Khvorov, A., Valkenburg, S. A., Cowling, B. J., & Barr, I. G. (2022) · Nature Communications · doi:10.1038/s41467-022-29402-5 · Cited by 256
Perelygina, L., Chen, M.-H., Suppiah, S., Adebayo, A., Abernathy, E., Dorsey, M., Bercovitch, L., Paris, K., White, K. P., Krol, A., et al. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1008080 · Cited by 87
Metadata
- Authors
- Memoli, M. J., Athota, R., Reed, S., Czajkowski, L., Bristol, T., Proudfoot, K., Hagey, R., Voell, J., Fiorentino, C., Ademposi, A., Shoham, S., & Taubenberger, J. K.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-01
- Volume
- 58
- Issue
- 2
- Pages
- 214-224
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2169491330
- Cited by
- 274
- References
- 26
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.